TTK Healthcare Reports FY25-26 Performance; Announces Sale of EVA and Good Home Brands

TTK Healthcare Reports FY25-26 Performance; Announces Sale of EVA and Good Home Brands​

TTK Healthcare Limited provided an update on its financial performance and strategic direction during the 68th Annual General Meeting held on July 24, 2026. The company announced definitive agreements for the divestment of its Consumer Products brands EVA and Good Home.

The Board also paid a heartfelt tribute to Mr T T Jagannathan, Former Chairman, who passed away on October 09, 2025. The tribute acknowledged his invaluable contributions to the company over nearly four decades.

Financial Highlights for FY 2025-26​

Addressing stakeholders, the Director delivered an overview of the company's financial performance during the year under review. Revenue from Operations stood at Rs.857.28 crores, marking a growth of around 7% compared to the previous year's figure of Rs.801.49 crores.

Pre-tax Profit after Exceptional Items was reported at Rs.82.56 crores, down from Rs.108.33 crores in the prior year. The decline in profit was primarily attributed to lower profitability in the Protective Devices Division due to the loss of Institutional and Tender business, particularly concerning USAID.

Key financial metrics for the year included:

• Earnings per Share (EPS): Rs.46.48 (Previous Year: Rs.57.79).
• Free Cash Balance: The company reported a free cash balance of around Rs.900 crores as at March 31, 2026.

Strategic Divestment of Consumer Brands​

As part of the strategic direction for its Consumer Products Division and given the current market scenario, the Board decided to divest EVA and Good Home, which were integral parts of the consumer portfolio. These brands generated a combined turnover of Rs.148 crores during FY 2025-26.

The definitive agreement for the sale has been signed with M/s Wipro Enterprises Private Limited. The transaction is valued at Rs.256 crores plus applicable GST, and the closing of the deal remains subject to customary conditions precedent. Directors expressed confidence that Wipro is well-positioned to drive these brands through their strong FMCG capabilities.

Business Segment Performance Review​

The company presented a detailed review of all its business segments for FY 2025-26, along with strategic plans for FY 2026-27.

Consumer Products Division (CPD):
The division faced challenges in the Woodward's Gripe Water (WGW) segment due to volume declines in Southern markets, although e-commerce and Modern Trade showed growth on a lower base. A national campaign, 'I Am Woodward's Baby,' was launched to reinforce brand trust. The launch of Woodward's Tummy Roll-On into the care segment was noted for its strengthening positioning. For 2026-27, initiatives include enhancing brand relevance through a new communication platform and expanding the 'Care' portfolio with the proposed launch of Tummy Tonic in Tamil Nadu, alongside wider distribution of Tummy Roll-On.

Animal Welfare Business (AWD):
The AWD reported a revenue growth of around 12%, driven by a stronger second half. While Bovianim and Gallus showed robust growth, Companim grew by 5% amid market challenges. The focus for the next fiscal year involves strengthening flagship brands through farm programmes and Key Opinion Leader (KOL) engagement, including revitalizing Companim’s portfolio.

Medical Devices Business:
The Heart Valve Division recorded a revenue growth of around 2%. Despite supply impacts due to the Russia-Ukraine conflict impacting CardiaMed BiLeaflet Valves, limited imports from the Russian manufacturer helped manage availability. The division plans to increase volumes of TTK Chitra Heart Valves. Furthermore, following the successful single-centric pilot study of the improved TC2 TTK Chitra Titanium Heart Valve, pivotal studies involving approximately 400 patients are planned subject to funding and regulatory approvals.
The Ortho Division achieved a strong revenue growth of 27%, supported by expansion into new regions and encouraging responses to the pilot launch of Citius Fixed Bearing Knee Implant. For 2026-27, the division plans nationwide rollout of Citius, expansion of its field force, and launching the Revision Hip Implant System.

Protective Devices Business:
This division reported a revenue growth of around 5%. Although initial difficulties arose from the cessation of USAID business and the absence of a long-term agreement with UNFPA, recovery was noted through new customer acquisitions. The company maintained its WHO-UNFPA pre-qualified supplier status and expanded its international product registrations. Future plans include strengthening contract manufacturing partnerships and commencing lubricant manufacturing at the Virudhunagar facility.

Pleasure Products Business:
The business, comprising Skore Pleasure Products, MsChief, and Love Depot, was marked by consolidation and capability building in FY 2025-26. Skore Pleasure Products showed healthy growth, driven by e-commerce performance in accessories and lubricants. MsChief saw strong growth through e-commerce and quick commerce channels. For the next fiscal year, the Pleasure Products Business aims to accelerate growth through innovation, portfolio expansion, and deeper consumer engagement across all brands.

Foods Business:
The Foods Division reported a revenue growth of 14%. Four new products developed at the Hosakote R&D Centre were commercialized, with a focus on protein-rich offerings. The division continued improving operational efficiency through various cost-saving initiatives. For FY 2026-27, priorities include optimizing the product mix for profitability and launching innovative, differentiated products.

Outlook and Dividend Recommendation​

The company’s outlook for 2026-27 remains positive, despite geopolitical instability and the West Asia Crisis. The Directors recommended a dividend of Rs.10.00 per share (i.e.) 100%, matching the previous year's rate.

TTKHLTCARE Stock Price Movement​

As of 2:59 PM, shares of TTK Healthcare Limited are edging higher to ₹1044.05, gaining 3.11% and posting a robust gain of ₹31.50 in live trading. The equity experienced active market interest with a volume of 25,754 shares traded as the day continues.